Jazz Pharmaceuticals (JAZZ) Misses Q4 EPS by 6c; Guides FY18 Relatively In-Line

Jazz Pharmaceuticals (NASDAQ: JAZZ) reported Q4 EPS of $2.95, $0.06 worse than the analyst estimate of $3.01. Revenue for the quarter came in at $436.4 million versus the consensus estimate of $441.31 million.

GUIDANCE:

Jazz Pharmaceuticals sees FY2018 EPS of $12.65-$13.25, versus the consensus of $13.07. Jazz Pharmaceuticals sees FY2018 revenue of $1.86-1.93 billion, versus the consensus of $1.85 billion.

For earnings history and earnings-related data on Jazz Pharmaceuticals (JAZZ) click here.

You May Also Be Interested In

• Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
• Ledyard Financial Group adds two directors, three retire
• Vera Bradley (VRA) Tops Q2 EPS by 10c ; Offers Guidance